N/A N=304 Way to Be Active I (Teams)
Sedentary Employees
Primary: Proportion of Days a Minimum Activity of 7000 Steps or More is Achieved — 0.176; 0.254; 0.173; 0.350 Proportion of participant-days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=10 Researching the Effects of Airway Clearance Therapies in Cystic Fibrosis
Cystic Fibrosis · Mucociliary Clearance Defect
Primary: Mucociliary Clearance-274 — 20.3; 16.8; 18.5; 19.1 percent clearance — p=0.615
Phase 4 N=26 A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders
Urea Cycle Disorder
Primary: Percentage of Participants With Successful Transition to RAVICTI With Controlled Ammonia (i.e. No Clinical Symptoms and Ammonia < 100 μmol/L): Cohort of 2 Months to <2…
Phase 2 N=189 Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively
Actinic Keratosis
Primary: Number of Participants Experiencing DLTs (Dose Limiting Toxicities) Based on LSRs (Local Skin Reactions) — 9; 0; 11 Participants
Phase 4 N=170 A Non-inferiority Trial on Pain Relief During Oocyte Retrieval
Infertility
Primary: Pain Level During Oocyte Retrieval — 0; 4; 2.5; 5 score on a scale
Phase 2 N=64 Study of Tremelimumab in Patients With Advanced Solid Tumors
Urothelial Bladder Cancer · Triple-negative Breast Cancer · Pancreatic Ductal Adenocarcinoma
Primary: Percentage of Patients With Confirmed Overall Response During Tremelimumab Monotherapy Phase — 18.8; 8.3; 0.0 Percentage of Patients
Phase 3 N=249 Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
Adult Kidney Wilms Tumor · Beckwith-Wiedemann Syndrome · Childhood Kidney Wilms Tumor
Primary: Event-Free Survival (EFS) — 0.82 Probability
Phase 3 N=45 Oral vs. Injectable Naltrexone for Hospitalized Veterans With Alcohol Dependence
Alcohol Dependence
Primary: Retention Rate: Percentage of Participants Attended an Initial Behavioral Treatment Visit Within 2 Weeks of Hospital Discharge. — 23; 22 Participants
Phase 2 N=23 Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Recurrent Ovarian Cancer · Fallopian Tube Carcinoma · Primary Peritoneal Carcinoma
Primary: Progression-free Survival Rate After 6 Months of Treatment on Study — 0 participants
N/A N=24 Clinical Evaluation of 2-Week Reusable ACUVUE 2 Vivid Style
Visual Acuity
Primary: LogMAR Objective Vision (High Illumination/High Contrast) — -0.105 logMAR
N/A N=124 Evaluation of the Efficacy and Tolerance of a Light Therapy Mask on Mild to Moderate Brown Spots and Moderate to Severe Facial Wrinkles
Skin Aging
Primary: Global Wrinkling - Change From Baseline to Week 12, Averaged Expert Grader Scores — 0.18; 0.30 Units on a scale — p=<0.001
N/A N=139 CPAP In-home Assessment USA
Obstructive Sleep Apnea
Primary: Apnea Hypopnea Index (AHI), Measured as Number of Events/Hour. — 1.9 events/hr
Phase 2 N=50 Theta-Burst Neuromodulation for PTSD
Chronic Post-Traumatic Stress Disorder
Primary: Number of Participants Retained, a Measure of Acceptability of TBS Procedures — 23; 24 Participants
N/A N=15 Clinical Evaluation of Two Monthly Contact Lenses
Refractive Errors
Primary: Subjective Rating of Overall Vision — 8.6; 8.6 units on a scale
N/A N=5 Functional Connectivity & Stimulation-enhanced Therapy Post Stroke
Stroke
Primary: Mean Change in Hand Motor Function — 0.83 blocks